Evidence map›Paper›PMID 32520208›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2020

Knocking down LSD1 inhibits the stemness features of colorectal cancer stem cells.

J Chen, Jianyong Zhao, J Ding, Ziwei Wang, Jiyi Du, Chenchang Wu

Open access · goldAbstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Targeting epigenetic regulators to overcome drug resistance in cancers.Signal transduction and targeted therapy · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

J ChenDepartment of Gastrointestinal Surgery, Guizhou Provincial Bijie City Qixingguan District People's Hospital, Bijie, China.ORCID http://orcid.org/0000-0003-2864-453X
Jianyong ZhaoDepartment of Gastrointestinal Surgery, Guizhou Provincial Staff Hospital, Guiyang, China.ORCID http://orcid.org/0000-0002-9752-0314
J DingDepartment of Gastrointestinal Surgery, Guizhou Provincial People's Hospital, Guiyang, China.ORCID http://orcid.org/0000-0003-1620-5839
Ziwei WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID http://orcid.org/0000-0002-2147-872X
Jiyi DuDepartment of Gastrointestinal Surgery, The First People's Hospital of Guiyang, Guiyang, China.ORCID http://orcid.org/0000-0003-3767-4677
Chenchang WuDepartment of Gastrointestinal Surgery, Guizhou Provincial Bijie City Qixingguan District People's Hospital, Bijie, China.ORCID http://orcid.org/0000-0002-8138-7459
Guizhou Provincial People's Hospital · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CNThe First People's Hospital of Guiyang · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a top leading cause of cancer death in many countries, colorectal cancer (CRC) has drawn increasing attention to the study of the pathological mechanism. According to the "cancer stem cell hypothesis", malignancies originate from a small fraction of cancer cells that show self-renewal properties to initiate and sustain tumor growth and tumor metastasis. Therefore, these cancer stem cells (CSC) probably play important roles in tumor recurrence, metastasis, and drug resistance. Previous research reported that lysine-specific histone demethylase 1 (LSD1) maintains cancer stemness through up-regulating stemness markers SOX2 and OCT4. CD133 is believed to be the most robust surface marker for CRC stem cells, however the regulatory effect of LSD1 on stemness of CD133+ CRC has never been reported. In this study, our objectives included: 1) to isolate pure CD133+ and CD133- cells from SW620 cell line; 2) to investigate the effect of LSD1 on the characteristics of CD133+ stem cancer cells by knocking down the target gene. Results suggested that the SW620 cell line had both CD133+ and CD133- subsets. The CD133+ subset exhibited more CSC-like characteristics compared with the CD133- subset with higher viability, colony formation rate, migration and invasion rate, resistance to anti-cancer drugs, and apoptosis in vitro. The CD133+ also induced faster tumor formation and larger tumors in vivo. In the LSD1-knockdown CD133+ cells, the CSC-like characteristics had been all weakened. We conclude that LSD1 was important for CSCs to maintain their "stemness" features, which could be a potential therapeutic target of CRC.

Indexed as

AnimalsApoptosisBlotting, WesternCell Line, TumorCell MovementCell ProliferationColony-Forming Units AssayColorectal NeoplasmsGene Expression Regulation, NeoplasticHistone DemethylasesHumansMiceNeoplastic Stem CellsHistone DemethylasesKDM1A protein, human

Identifiers

PMID32520208
PMCPMC7279696
OpenAlexW3029929236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.